ABSTRACT Preincubation of Swiss 3T3 cells or human fibroblasts with purified platelet-derived growth factor (PDGF) at 4°C or 37°C rapidly inhibits subsequent binding of 12~l-epidermal growth factor (12SI-EGF). The effect does not result from competition by PDGF for binding to the EGF receptor since (a) very low concentrations of PDGF are effective, (b) cells with EGF receptors but no PDGF receptors are not affected, and (c) the inhibition persists even if the bound PDGF is eluted before incubating the ~:ells with ~2~I-EGF. PDGF does not affect 12Sl-insulin binding nor does EGF affect 12~I-PDGF binding under these conditions. Endothelial cell-derived growth factor also competes for binding to PDGF receptors and inhibits t251-EGF binding. The inhibition demonstrated by PDGF seems to result from an increase in the Kn for ~251-EGF binding with no change in the number of EGF receptors.
A number of substances have been shown to affect L25I-EGF binding to cells after a period of preincubation at 37°C, ineluding dexamethasone (1), fibroblast-derived growth factor (2), vasopressin (3) , and lipid-interacting substances (4) . Lee and Weinstein (5) found that different phorbol esters could inhibit L25I-EGF binding in proportion to their potency as tumor promoters. The effect is temperature-dependent (3, 6, 7, 8) and seems to reflect a decrease in the affmity of the EGF receptor (3) , possibly by eliminating a high affinity class of EGF receptors (8) . Phorbol acetate does not seem to affect L25I-insulin binding (7) . Phorbol esters seem to have specific binding sites on responsive ceils (9, 10) , so it is possible that their effect on EGF binding is mediated through a specific receptor.
Recently, incubation with PDGF at 37°C has been shown to decrease the binding of t2~I-EGF (11, 12, 13) , reportedly by reducing the number of EGF receptors (11, 13). PDGF is the major mitogen in serum for many connective tissue cells in culture (14, 15, 16) . At 37°C cells respond rapidly to PDGF with changes in several processes that could have secondary effects on receptors for EGF and other growth factors. PDGF stimulates the phosphorylation of cytoplasmic proteins on tyrosine within 1 min (17), increases phosphatidylinositol turnover within 2 min (18) , phosphorylation of a 33-dalton cell protein within 3 min (19) , the appearance of membrane ruffles and microvitli within 20 min (20) , and increased amino acid uptake within 1 h (21) . Over a period of several hours, PDGF increases the number of LDL receptors (22, 23) and somatomedin C receptors (24) 2 min (26), hexose uptake within 10 min (25) , and phosphofructokinase activity within 30 min (27) . This series of complex responses makes it difficult to distinguish direct interaction between PDGF and EGF receptors from effects which are secondary to the metabolic effects of PDGF. In an attempt to reduce the possibilities for secondary effects of PDGF on EGF receptors, we have investigated the effects of PDGF and other hormones on mSI-EGF binding in a system in which both pretreatment and binding determinations are performed at 4°C.
MATERIALS AND METHODS
The Swiss mouse 3T3-DI cells used in most of the studies reported here were cloned from Swiss 3T3 cells obtained from R. Pollack (State University of New York at Stony Brook). The A-431 human carcinoma ceUs were obtained from B. Gallis (University of Washington, Seattle). The adult human diploid foreskin fibroblasts (HF) were obtained essentially as described by Baker et al. (1) . The variant 3T3-PF2 cell was selected by [aH]thymidine suicide against mitogenic response to PDGF, as described in Bowen-Pope and Ross (28) , and recloned for these experiments (now designated 3T3-PF2 (f)). Culture methods were those previously described (28) . Binding of 12~I-ligand was initiated, as described in the figure and table legends, either by adding 50/xl of ~2'~l-ligand directly to the preincubation medium or by rinsing the cultures and incubating with fresh binding medium containing 12Sl-ligand alone. The methods for determining specific binding were those previously described (28) . Nonspecific binding of t25I-PDGF and I~I-EGF averaged I-3% and 5-15%, respectively, of total binding. PDGF was radioiodinated to a specific activity of about 40,000 cpm/ng, essentially as previously described (28) . EDGF was prepared from serum-free conditioned medium of confluent bovine aortic endothelial cells as previously described (29) . Briefly, the medium was centrifuged for 6 × 10" g-minutes, concentrated 30-fold by ultrafiltration (final protein concentration 655 pg/ml), and dialyzed exhaustively against 1 mM ammonium bicarbonate. ~l-insulin and ~'~I-EGF were obtained from New England Nuclear (Boston, MA). Highly purified human PDGF was prepared as previously described (30 As expected, E~I-PDGF binding is reduced by competition with unlabeled PDGF for the PDGF receptor (28, 3l) . Unexpectedly, the preincubation with PDGF also reduces subsequent 12~I-EGF binding (Fig I a) , even though all incubations were performed at 4°C to prevent internalization of bound ligand (32, 33, 34) and possible cointernalization of PDGF and EGF receptors. Inhibition of ~I-EGF binding is detectable with concentrations of PDGF too low to produce measurable competition for I~I-PDGF binding under these conditions. The maximal effect of PDGF in this experiment is a 60% decrease in ]~I-EGF binding at 2 ng/ml PDGF, with no further decrease occurring at higher concentrations of PDGF. The converse effect is not seen, i.e., preincubation with EGF at concentrations sufficient to saturate the EGF receptor does not affect r~5I-PDGF binding (Fig. I b) . The small reduction in t"~I-PDGF binding seen in this experiment was not reproducible.
RESULTS

Reduction of ~2~I-EGF Binding by Preincubation with PDGF at 4 °C
Mediation through PDGF Receptors
The concentration dependence of PDGF inhibition of ~251-EGF binding suggested that the effect is mediated through PDGF receptors and not through a direct effect of PDGF on EGF receptors. To look for direct effects we used A-431 cells, which have EGF receptors but not PDGF receptors (28, 31, 35) . Even extremely high concentrations of PDGF (120 ng/ml) do not reduce ~25I-EGF binding to A-431 cells (data not shown). We have also selected a variant line of 3T3 cells (3T3-PF2 (f)) that shows a greatly reduced mitogenic response to PDGF and expresses only ~5% of the parental number of PDGF receptors per cell (28) , but that expressed the parental number of EGF receptors. Fig 2 shows that PDGF reduces ~2~I-EGF binding to these ceils, but to a much smaller extent than it does to normal 3T3 ceils. This suggests that the inhibition of I~I-EGF binding by PDGF is proportional to the number of PDGF receptors present. However, until the biochemical nature of the defect in clone PF2(f) is known, we cannot use this cell line to make any exact calculations as to the relationship between occupied PDGF receptors and inhibition of EGF binding. Inhibition of ~z~I-EGF binding by PDGF is not unique to 3T3 cells since binding of ~I-EGF to diploid human fibroblasts, which express both PDGF and EGF receptors (28, 31, 32) , is also reduced by preincubation at 4°C with PDGF ( Fig. 2) .
Simultaneous Occupation of the PDGF Receptors is Not Required
In the previous experiments PDGF was present prior to, and during, incubation with 12~I-EGF. To determine whether the inhibition of 125I-EGF binding requires continuous occupation before measuring L25I-EGF binding. Binding of 12~I-EGF was still inhibited. However, PDGF dissociates so slowly from its receptor at 4°C (31) that most receptors occupied during the preincubation period would remain occupied during the incubation with E25I-EGF. To remove bound PDGF, we adapted the method of Haigler et al. (36) to remove cell surface-bound '25I-EGF. A 3-min incubation at 4°C with 0.1% acetic acid in 150 mM NaCI with 0.1% BSA removed 89% of prebound ]251-PDGF and 78% of prebound '25I-EGF (data not shown). Neither the 4°C preincubation nor the acetic acid rinse damaged the cells or receptors as measured by three criteria (a) <2% of the cells stained with the dye trypan blue, even after a 4-h incubation at 4°C in binding medium followed by an acetic acid rinse. (b) Binding of '25I-EGF and ~25I-PDGF to acidtreated cultures was 10t% and 103%, respectively, of binding to untreated cultures. (c) Cultures of 3T3 cells incubated in binding medium for 4 h at 4°C, then rinsed with acetic acid, were able to respond normally to subsequent addition of 5 ng/ ml EGF (3.7-fold stimulation in control, 3.2-fold stimulation in treated cultures) or PDGF (5.l-fold stimulation in control, 4.4-fold stimulation in treated cultures) as assayed by [~H]-thymidine incorporation determined 20 h later. Table I shows that the acid rinse eliminated the effects of preincubation with PDGF on subsequent '2~I-PDGF binding, presumably by releasing prebound ligand, but did not significantly lessen the inhibition of subsequent v'~I-EGF binding. This demonstrates that PDGF is not acting by sterically blocking ~25I-EGF binding and that the effect of PDGF is stable for at least the time needed to assay 125I-EGF binding.
Kinetics of Inhibition
At 4°C the effect of PDGF on '~SI-EGF binding is rapid but not immediate (Fig. 3) . A portion of the time (about 10 min) needed to produce a 50% decrease in subsequent ~25I-EGF binding probably reflects the time needed for binding of PDGF to its receptor (e.g., see reference 28 for binding kinetics under these conditions). However, some time after binding is also required to develop the full effect, since the inhibition produced FIGURE 3 Time course of effect of PDGF on subsequent '251-EGF binding. Confluent quiescent cultures of 3T3 D1 cells were rinsed with cold PBS and incubated at 4°C in binding medium with 10 ng/ml PDGF. After the times indicated on the abscissa the cultures were rinsed twice with PBS and incubated for 3 rain at 4°C with either PBS (0) or 0.1% acetic acid in 150 mM NaCI with 0.5% BSA (O). These solutions were aspirated and the cultures incubated for 1 h at 4°C in binding medium with 0.25 ng/ml 1251-EGF. Specific binding (mean + SEM of determinations on triplicate cultures) was determined as described in Materials and Methods, and is plotted as % of the value obtained without exposure to PDGF.
by short preincubation with PDGF is considerably less when the bound PDGF is removed with acetic acid before assaying ~25I-EGF binding, than when the PDGF remains bound throughout the assay period (Fig. 3) . This cannot be due to instability of the inhibition once established, since dissociation of bound PDGF has little effect after a preincubation of 2 h or more (Table I and Fig. 3 ). Table I shows that PDGF is able to inhibit '251-EGF binding. The inhibition by unlabeled EGF presumably represents steric competition for EGF receptors, since it is eliminated by removing prebound EGF with acetic acid. Binding of ~25I-EGF is also inhibited by a factor produced by cultured vascular endothelial cells in serum-free medium (Table I) . Since endothelial cell-derived growth factor (ECDGF) does not block binding of '2~I-EGF to cells without PDGF receptors (unpublished observations), and since ECDGF seems to bind to PDGF receptors (28) , it seems likely that the inhibition of ]25I-EGF binding by ECDGF is also mediated through the PDGF receptor. In three experiments, fibroblast growth factor (FGF) had a smaller, though statistically significant, effect on '2~I-EGF binding under these conditions (Table I) . Although the preparation of FGF is estimated to be only 10% pure, it is unlikely that contamination by EGF is responsible for the inhibition of ]25I-EGF binding since the inhibition was not reversed by acetic acid rinsing. Significant contamination by PDGF is also unlikely since ]25I-PDGF binding is not significantly reduced by 10 #g/ml FGF (28) . High concentrations of insulin had no effect (Table I ). The converse interaction, i.e., inhibition of ~25I-PDGF binding by preincubation with EGF, does not occur (Fig. i b and Table I ).
Specificity of Inhibition of EGF Binding
To investigate the specificity of PDGF inhibition of ligand binding we investigated the sensitivity of ~2~I-insulin binding to inhibition by PDGF. Even extremely high concentrations of PDGF (400 ng/ml) did not reduce specific ~2~I-insulin binding to 3T3 cells (data not shown). Scatchard analysis of ~2SI-EGF binding. (a) Confluent quiescent cultures of 3T3-D1 were preincubated for 2 h at 4°C in binding medium without PDGF (O), with 0.5 mg/ml PDGF (O), or with 10 ng/ml PDGF (ll). Preincubation was terminated by rinsing with PBS and was followed by incubation for 2 h at 4°C in binding medium with concentrations of 1251-EGF from 0.5 to 225 ng/ml. Specific t2SI-EGF binding (mean + SEM of determinations on triplicate cultures) was determined as described in Materials and Methods. (b) Cultures were preincubated for 2 h at 37°C in bicarbonatebuffered medium without PDGF (0) or with 10 ng/ml PDGF ((3). Subsequent analysis was as described for (a).
Scatchard Analysis
cannot be calculated for PDGF-preincubated cultures due to the pronounced curvature of the plot at low concentrations of EGF. However, from binding saturation plots we calculate that cultures preincubated with 0, 0.5, or 10 ng/ml PDGF show half-maximal 125I-EGF binding at 1.3, 1.6, and 2.0 nM, respectively, and express 40,200, 41,700, and 43,800 EGF receptors/ cell, respectively. After pretreatment with either concentration of PDGF, the maximum ratio of bound to free 125I-EGF occurs when -12% of the EGF receptors are occupied. Fig 4b shows that preincubation of 3T3 cell cultures with 10 ng/ml PDGF at 37°C for 2 h causes a similar, though more pronounced, decrease in the apparent Kd of ~2SI-EGF binding with no significant decrease in the apparent number of EGF receptors.
DISCUSSION
We have found that PDGF can reduce the binding of low concentrations of ~25I-EGF by up to 80%, even when the cells are maintained at 4°C throughout the preincubation and measurement periods. This distinguishes PDGF from other inhibitors of 125I-EGF binding that have been shown to require a period of incubation at 37°C to become effective (1, 3, 6, 7, 8, 32, 34) . We have demonstrated that inhibition does not result from direct competition by PDGF for 125I-EGF binding, nor from a general inhibition of specific ligand binding. These fmdings suggest that caution must be used in interpreting the results of"competition" studies, including radioreceptor assays performed using living ceils, since there seems to be significant interaction between the two different receptor systems, even at 4°C.
We can only speculate on the mechanism through which PDGF is affecting the EGF receptor. The process seems to be "catalytic" rather than stoichiometric in that occupation of the relatively small number of PDGF receptors produces half maximal inhibition of 12SI-EGF binding. Internalization of EGF receptors in response to PDGF binding to its own receptor ("cointernalization") does not seem to be involved, since PDGF can inhibit 12~I-EGF binding even at 4°C and since the affmity, but not the number, of EGF receptors is reduced. Among the ligand-induced changes that are not prevented by
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T.E JOURNAL O~: CELL BIOLOGY, VOLUME 96, 1983 incubation at 4°C, two processes appear to be relatively good candidates for involvement in the interaction between the two receptor systems--stimulation of protein kinase activity and clustering of receptors.
Although most energy-dependent reactions are greatly reduced at 4°C, the activity of the EGF-and PDGF-stimulated, tyrosine-specific protein kinases in membrane preparations is still substantial at 4°C (37, 38, 39 , and our unpublished observations). In each case, one of the substrates for the kinase seems to be the receptor for the activating ligand (39, 40) . It is possible that binding of PDGF to its receptor stimulates phosphorylaLion of the EGF receptor as well as of its own receptor. Unfortunately, we have not yet been able to resolve phosphorylated PDGF and EGF receptors on SDS polyacrylamide gels due to their very similar size (150,000-170,000 daltons) (39, 40, 41, 42, 43) . The effect of phosphorylation on the properties of the receptors is not known. However, phosphorylation-dephosphorylation reactions have been shown to affect the enzymatic activities of several regulatory enzymes (reviewed in reference 44). The effect ofphosphorylation on enzymes can be to change the Km for a substrate, the Ka for an activator, or the Ki for an inhibitor (44) . If PDGF-stimulated phosphorylation of the EGF receptor were involved in the inhibition of L~SI-EGF binding, the site(s) of phosphorylation may be different from the site(s) phospborylated in response to EGF binding, since removal of EGF (but not of PDGF) restores the binding properties of the EGF receptor. Hunter and Cooper (45) and Gates and King (46) have reported that the EGF receptor can be phosphorylated at multiple sites. Possibly PDGF stimulates phosphorylation of a very stable site.
Another candidate for involvement in the PDGF inhibition of EGF binding is an induced aggregation of EGF receptors with PDGF receptors. Some receptors seem to be present in small patches even before ligand addition. Low density lipoprotein (LDL) receptors are largely preconcentrated in coated pit regions (47) . Large-scale patching and internalization of receptors does not occur at 4°C (33, 34, 36) . Nevertheless, several receptors have been shown to be mobile in the plasma membrane to 4°C (48, 49) and to form small aggregates in response to ligand binding (48) . It is possible that the inclusion of an EGF receptor in the same aggregate as PDGF receptors could influence its ability to bind 12~I-EGF. Certainly, receptors are sensitive to general changes in their local environment. Phospholipase C and other lipid-interactive substances seem to decrease the affinity of 125I-EGF binding to mink lung ceils (4) , and removal of the EGF receptor from the membrane into Triton micelles reduces its affinity for EGF by 10-fold (50) . Changes in other membrane proteins associated with receptors have also been implicated in changes in receptor properties. Maturo and Hollenberg (51) reported a membrane glycoprotein whose association with the solubilized, partially purified insulin receptor altered its apparent affinity for 125I-insulin.
It is intriguing to speculate on the possible significance of this phenomenon for cell behavior. Dicker and Rozengurt (52) reported that phorbol acetate and EGF had synergistic effects in stimulating DNA synthesis, despite the fact that phorbol acetate reduces 12~I-EGF binding. Wolfe et al., (53) reported that EGF does not down-regulate its own receptor if HeLa ceils are cultured in defined medium without serum. PDGF may represent the component in serum which is necessary for the down-regulation of the EGF receptor in this system. It is thus possible that the inhibition of 12SI-EGF binding by PDGF that we have described in this report is only one manifestation of the interaction between the PDGF and EGF receptors, i.e., PDGF may also alter the ability of the EGF receptors to affect intracellular events or to be internalized and degraded. In any case, the ability of one growth factor to alter the properties of receptors for a second growth factor adds another locus to the sites at which the different polypeptide hormones could interact to potentiate or inhibit their physiological effects.
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